Auryxia was Akebia Therapeutics’s largest product and service line in fiscal 2025, bringing in $181.54M of $236.20M (77%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Auryxia | — | $170.30M | $152.18M | $181.54M | |||||
| Product Revenue, Net | $176.95M | — | — | — | |||||
| License, Collaboration & Other Revenue | $115.54M | $24.32M | $8.00M | $8.86M | |||||
| Vafseo | — | — | — | $45.79M | |||||
| Total | $292.48M | $194.62M | $160.18M | $236.20M |
Akebia Therapeutics brought in $236.20M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Akebia Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $160.18M. Auryxia was the largest at $181.54M (76.9%), ahead of Vafseo at $45.79M (19.4%) and License, Collaboration & Other Revenue at $8.86M (3.8%).
Compared with fiscal 2024, Auryxia grew 19.3% to $181.54M and License, Collaboration & Other Revenue grew 10.8% to $8.86M.
Akebia Therapeutics began breaking out Auryxia in fiscal 2023 and Vafseo in fiscal 2025. Akebia Therapeutics stopped reporting Product Revenue, Net as a separate line after fiscal 2022, when it brought in $176.95M.
Total Proportional Performance Revenue was Akebia Therapeutics’s largest revenue line in fiscal 2018, bringing in $200.47M of $209.88M (96%).
| Counterparty Name | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|
| Otsuka Pharmaceutical Company. Ltd | — | $138.28M | — |
| Total Proportional Performance Revenue | — | — | $200.47M |
| Mitsubishi Tanabe Pharma Corporation & Otsuka Pharmaceutical Company Limited | $1.54M | — | — |
| Mitsubishi Tanabe Pharma Corporation | — | $42.92M | $9.30M |
| Jt & Torii | — | — | $112.00K |
| Total | $1.54M | $181.20M | $209.88M |
Akebia Therapeutics brought in $209.88M from its three revenue lines in fiscal 2018, the year ended December 31, 2018. Akebia Therapeutics regrouped these revenue lines after fiscal 2017, so the total does not compare directly with that year's $181.20M. Total Proportional Performance Revenue was the largest at $200.47M (95.5%), ahead of Mitsubishi Tanabe Pharma Corporation at $9.30M (4.4%) and Jt & Torii at $112.00K (0.1%).
Akebia Therapeutics began breaking out Total Proportional Performance Revenue in fiscal 2018, Mitsubishi Tanabe Pharma Corporation in fiscal 2017 and Jt & Torii in fiscal 2018. Akebia Therapeutics stopped reporting Otsuka Pharmaceutical Company. Ltd ($138.28M in fiscal 2017) and Mitsubishi Tanabe Pharma Corporation & Otsuka Pharmaceutical Company Limited ($1.54M in fiscal 2016) as separate revenue lines.
Development & Commercialize United States Collaboration And License Agreement was Akebia Therapeutics’s largest revenue line in fiscal 2017, bringing in $86.00M of $178.00M (48%).
| Type Of Arrangement | FY 2016 | FY 2017 |
|---|---|---|
| Development & Commercialize International Collaboration And License Agreement | — | $52.30M |
| Development & Commercialize United States Collaboration And License Agreement | $1.54M | $86.00M |
| Development & Commercialize Collaboration Agreement | — | $39.70M |
| Total | $1.54M | $178.00M |
Akebia Therapeutics brought in $178.00M from its three revenue lines in fiscal 2017, the year ended December 31, 2017. Akebia Therapeutics regrouped these revenue lines after fiscal 2016, so the total does not compare directly with that year's $1.54M. Development & Commercialize United States Collaboration And License Agreement was the largest at $86.00M (48.3%), ahead of Development & Commercialize International Collaboration And License Agreement at $52.30M (29.4%) and Development & Commercialize Collaboration Agreement at $39.70M (22.3%).
Akebia Therapeutics began breaking out Development & Commercialize International Collaboration And License Agreement in fiscal 2017 and Development & Commercialize Collaboration Agreement in fiscal 2017.
Akebia Therapeutics (AKBA) reports its revenue by product and service, by counterparty name and by type of arrangement. In fiscal 2025, Auryxia was its largest product and service line, bringing in $181.54M (76.9% of the total), followed by Vafseo at $45.79M (19.4%).
Auryxia was Akebia Therapeutics' largest product and service line in fiscal 2025, bringing in $181.54M, or 76.9% of the $236.20M total across its three product and service lines.
Total Proportional Performance Revenue was Akebia Therapeutics' largest revenue line in fiscal 2018, bringing in $200.47M, or 95.5% of the $209.88M total across its three revenue lines.
Every figure comes from Akebia Therapeutics' annual financial filings, as reported. Each line keeps the name Akebia Therapeutics gives it, and years follow its fiscal calendar.
Akebia Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.